Vimarsana
Biggest News Aggregation in the World

Daichi Sankyo News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Daichi Sankyo. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Daichi Sankyo Today - Breaking & Trending Today

Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy - Vimarsana News

Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy

This clinical trial compares the effectiveness of anticoagulation vs antiplatelet therapy for secondary stroke prevention in patients with cryptogenic stroke an

india: 'Many Japanese cos see India as a partner of choice' - Vimarsana News

india: 'Many Japanese cos see India as a partner of choice'

Daiwa Securities Group Inc, a Japanese financial services firm, plans to expand its presence in India through an investment in Ambit. The company sees India as an ideal partner in the current global economic and political order. Daiwa first entered India in 2007 but faced difficulties scaling up its business.

Profit Taking May Contribute To Initial Pullback On Wall Street - Vimarsana News

Profit Taking May Contribute To Initial Pullback On Wall Street

The major U.S. index futures are currently pointing to a lower open on Wednesday, with stocks likely to move to the downside as trading resumes following the Independence Day holiday on Tuesday.

Asian Shares Decline As Chinese Growth Worries Mount - Vimarsana News

Asian Shares Decline As Chinese Growth Worries Mount

Asian stocks ended mostly lower on Wednesday after new data showed China's economy continued to struggle in June. Investors also looked ahead to the release of the Federal Reserve's latest monetary policy meeting minutes as well as the U.

Pfizer's Seagen Acquisition Brings It Full Circle in a Hot Area of Cancer Drug R&D - Vimarsana News

Pfizer's Seagen Acquisition Brings It Full Circle in a Hot Area of Cancer Drug R&D

Pfizer is no stranger to antibody drug conjugate cancer therapies, but it hasn’t been commercially successful with them. The pharma giant’s agreement to acquire Seagen for $43 billion will thrust it to the forefront of the ADC drug class, which has become a hot space for research and regulatory activity in recent years.